STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir (STO:MVIRB) has participated in, and was today presented before, the Acumen BioFin Rodman & Renshaw 5th Annual Healthcare Conference in Monaco. The presentation provides an update on Medivir's projects, including the newly signed deal with Tibotec on HCV polymerase inhibitors.
